Shares of Remote Monitored Systems (LON: RMS) have followed Thursday's gains with another rally after the company said the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters, has been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Yesterday saw RMS shares closed 18% higher after announcing a distribution agreement between its subsidiary, Pharm 2 Farm, and Vivek Kohli Enterprises.
In the past year, RMS said Pharm 2 Farm and Volz have established a close working relationship, with Volz manufacturing the existing 4-ply anti-viral masks for Pharm.
The two companies have also been developing a new anti-viral filter material as an extension of the work on the anti-viral mask covered by the same patent.
Antony Legge, Executive Chairman, said: “Volz have been an excellent partner to Pharm 2 Farm, providing support in a number of areas. We are delighted with the MHRA approval for the 5-ply mask and to be working with Volz on an exciting development of the α-virion technology, with the potential to incorporate it into air filters.”
RMS' share price is currently trading at 1.194p, up 14.86%, adding to Thursday's rise.
Should you invest in Remote Monitored Systems shares?
Remote Monitored Systems shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are RMS shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies